This study will use \[18F\]-AraG PET/CT scans to monitor patients who have been diagnosed with locally advanced Head and Neck Squamous Cell carcinoma (LA-HNSCC), and are planning to undergo standard of care chemoradiotherapy for treatment.
Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer globally. Definitive chemoradiotherapy (CRT) remains the standard of care (SOC) treatment for LA-HNSCC, yet some patients are unsuccessfully treated. The purpose of this study is to explore the feasibility and possible function of \[18F\]-AraG PET/CT (a diagnostic procedure that uses a radioactive tracer \[A method that uses radioactive substances to make pictures of areas inside the body\] to image tumors and assess response to treatment) scans performed before and during treatment to monitor response in patients undergoing chemoradiotherapy.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
5
\[18F\]-AraG radiotracer, which occurs on the first and sixteenth day of treatment.
Concurrent chemoradiotherapy (CRT) with weekly doses of cisplatin.
Concurrent chemoradiotherapy (CRT) of 70Gy of radiation dose in 33 fractions.
Indiana University
Indianapolis, Indiana, United States
[18F]-AraG PET/CT uptake and infiltrating cytotoxic T-cell expression.
Examining the distribution of \[18F\]-AraG PET SUV metrics and counts of CD3+/CD8+/PD1- and CD3+/CD8+/PD1+ T-cells
Time frame: Week 1 and Week 16
Pre-treatment [18F]-AraG PET/CT uptake and clinical response.
Correlation of pre-treatment \[18F\]-AraG PET/CT metrics (such as SUVmax, mean and uptake volume) and clinical response.
Time frame: Pre-treatment
Changes between pre-treatment and mid-treatment [18F]-AraG PET/CT uptake and clinical response
Correlation between percentage changes in PET uptake values (max, mean, and peak) at pre- and mid-CRT and treatment response categories.
Time frame: Pre-treatment and Week 16
Individual cytotoxic T-cell activities (CD3+, CD8+, PD1-, and PD1+) and pre-treatment [18F]-AraG PET/CT uptake
Correlation between individual cytotoxic T-cell activities (CD3+, CD8+, PD1-, and PD1+) and pre-treatment \[18F\]-AraG PET/CT uptake.
Time frame: Pre-Treatment
Tumor extent and standard uptake values between FDG PET and [18F]-AraG PET/CT imaging
Identify accuracy in tumor extent and standard uptake values between FDG PET and \[18F\]-AraG PET/CT imaging.
Time frame: treatment planning through post treatment ( up to 6 months)
[18F]-AraG PET/CT uptake over time and progressive-free survival
Association between the pattern of change in \[18F\]-AraG PET/CT uptake over time and progressive-free survival.
Time frame: up to 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.